

COMMENT OPEN



COVID-19 vaccination is not associated with reduced SGA or low Apgar score

Amr Ehab El-Qushayri ¹✉

© The Author(s) 2023

Pediatric Research (2024) 95:1172–1173; <https://doi.org/10.1038/s41390-023-02875-w>

Dear Editor,

Since the introduction of COVID-19 vaccines, substantial improvement has been noticed regarding severity, hospital and ICU admission and mortality of COVID-19.¹ Per se, the clinical society started to test the different types of vaccines on pregnant women, and it is safety was measured by pregnancy outcomes.

The article of Zhang et al.² demonstrated that vaccinated pregnant women were associated with a significant reduction of small gestational age (SGA) and low Apgar score at 5 min (<7) prevalence. Despite the fact that the authors included all the reported evidence regarding the safety of COVID-19 vaccination during pregnancy, the paper had some methodological and statistical concerns that progressed to results' bias.

First, the significance of the two outcomes, SGA and low Apgar score at 5 min (<7), was driven by only one paper (Magnus et al. 2022),³ which weighted 61.3% and 47.3% in both outcomes, respectively. Therefore, by performing sensitivity analysis by removing the largest weight study (Magnus et al. 2022), the

significance of both outcomes was lost (odds ratio (OR): 1, 95% confidence interval (CI): 0.95–1.05, $p = 0.87$) and (OR: 0.91, 95% CI: 0.82–1.01, $p = 0.07$) for SGA and low Apgar score at 5 min (<7), respectively (Figs. 1 and 2). Fixed effect model was used due to the absence of significant heterogeneity ($p > 0.05$).

Second, the authors included two duplicate papers including similar populations, Goldshtein et al. (2021)⁴ and Goldshtein et al. (2022).⁵ The two studies were conducted in the same country, had nearly similar authors, and in both studies, women received BNT162b2 vaccination. Moreover, the study of Goldshtein et al. (2021) included pregnant women who were vaccinated from December 19, 2020, till February 28, 2021, while the Goldshtein et al. (2022) included all singleton live births from March 1, 2021, till September 31, 2021, which means that their mothers were pregnant at least 7 months before such date and this observation increases the possibility that both populations were the same.

Despite the fact that COVID-19 vaccines exhibited beneficial efficacy outcomes, they were not associated with a reduction of




Fig. 1 The association between SGA and COVID-19 vaccination represented by the odds ratio (OR) and the 95% confidence interval (95% CI).

¹Faculty of Medicine, Minia University, Minia, Egypt. ✉email: amrehab11111@gmail.com

Received: 11 October 2023 Accepted: 18 October 2023

Published online: 31 October 2023




Fig. 2 The association between low Apgar score at 5 min (<7) and COVID-19 vaccination represented by the odds ratio (OR) and the 95% confidence interval (95% CI).

SGA and low Apgar score at 5 min (<7). More studies—in particular randomized ones—are still needed to confirm if COVID-19 vaccines are associated with a high safety margin and could significantly prevent adverse pregnancy outcomes.

REFERENCES

- Mohammed, I. et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. *Hum. Vaccin. Immunother.* **18**, 2027160 (2022).
- Zhang, D. et al. Systematic review and meta-analysis of neonatal outcomes of COVID-19 vaccination in pregnancy. *Pediatr. Res.* 2023;94:34–42.
- Magnus, M. C. et al. Association of SARS-CoV-2 vaccination during pregnancy with pregnancy outcomes. *JAMA* **327**, 1469–1477 (2022).
- Goldstein, I. et al. Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women. *JAMA* **326**, 728–735 (2021).
- Goldstein, I. et al. Association of BNT162b2 COVID-19 vaccination during pregnancy with neonatal and early infant outcomes. *JAMA Pediatr.* **176**, 470–477 (2022).

AUTHOR CONTRIBUTIONS

AEE-Q was responsible for the study design, analysis and writing of the full report.

FUNDING

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

COMPETING INTERESTS

The author declares no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Amr Ehab El-Qushayri.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023